Real-world clinical outcomes of the combination of anti-PD-1 antibody, trastuzumab, and chemotherapy for HER2-positive gastric/gastroesophageal junction cancer.
Baorui LiuZhan ShiXin ZhangQin LiuXiaobin CuiLin LiBaorui LiuJia WeiPublished in: Cancer medicine (2023)
This real-world study validated the combination regimen's high efficacy and good tolerance in patients with HER2-positive gastric/GEJ cancer. An increased incidence of brain metastasis was observed in patients who failed this regimen.